CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
What you need to know about credit card rewards and taxes can save you money. Equip yourself with essential tips for smart financial management.
28,655 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
A U.S. mortgage lender scrapped its first AI platform after weak adoption and replaced it with an integrated system t...
A $500k annuity promises $2,950 a month for life, but a deeper look shows significant trade-offs in inflation, liquid...
Ford kicked off the year with strong truck demand and a raised outlook. Now the automaker aims to sustain momentum in...
Polestar stock plunged 29% in a single week. There was no obvious single news trigger, but a mix of market forces and...
Rising oil prices amid escalating tensions weigh on the Dow and broader U.S. markets. This guide breaks down why ener...
As the Fed hints at slower rate moves, crypto markets stir. This guide explains what the federal reserve signals good...
A striking insider move from Elevance Health’s chairman raises questions for investors. This article breaks down what...
When SpaceX first hit the public markets, traders expected spectacle but not necessarily sustainability. A surprising...
Duolingo stock fell February as investors reeled from a shaky user metric and rising AI disruption concerns. This art...
Palantir faced a sharp 34% drop in the first half of 2026 as AI market expectations and earnings jitters weighed on s...
A new wave of personal AI assistants promises to act before you ask, with Town leading a $55 million round to connect...